Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Globe Newswire•30/09/2026•09:14 ET
0
Key Highlights
- ➤October 14, 2026 KOL investor event scheduled for SGT-610 (SLGL)
- ➤SGT-610 is Phase 3, orphan- and breakthrough-designated for Gorlin Syndrome
- ➤SGT-610 targets prevention of new basal cell carcinoma lesions
- ➤SGT-610 may offer improved safety versus oral hedgehog inhibitors
NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York.
The event will feature Julie Breneiser, PA-C (Gorlin Syndrome Alliance), Ervin Epstein Jr., MD (Alta Bates Summit Medical Center), Kavita Sarin, MD, PhD (Stanford Cancer Institute), and Elizabeth M. Billingsley, MD, FAAD, FACMS, FASDS (Penn State College of Medicine), who will discuss the significant disease burden of Gorlin Syndrome patients and lack of effective therapies.
Get started
Create a free account to read the full story.